2025 Annual Meeting | C23 - Anti-amyloid Therapy Boot Camp

Date Saturday 04/05/25

Time 12:00 PM - 04:30 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Half-Day Course

Director(s) Jonathan Graff-Radford, MD, FAAN

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Participants should be able to appraise major findings from recent clinical trials of anti-amyloid monoclonal antibody therapies in Alzheimer's disease; understand imaging and fluid biomarkers relevant for treatment eligibility and monitoring; identify proposed clinical criteria for appropriate use of anti-amyloid therapies in clinical practice; summarize mechanisms, risk factors, and safety monitoring for amyloid-related imaging abnormalities; and assess practice-level adaptations needed for emerging AD therapies.

CME Available 4.00 CME credits

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Advanced

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student, Business Administrator, Coordinator

Teaching Styles Case-based, Didactic

Event Timeline
12:00 PM - 12:25 PM PDT	Speaker	Updates on Anti-amyloid therapy Vijay K. Ramanan, MD, PhD
12:25 PM - 12:50 PM PDT	Speaker	Updates in Appropriate Use Criteria Judith L. Heidebrink, MD
12:50 PM - 01:15 PM PDT	Speaker	Using Biomarkers in Clinic Practice Vijay K. Ramanan, MD, PhD
01:15 PM - 01:40 PM PDT	Speaker	Comparing anti-amyloid therapies Judith L. Heidebrink, MD
01:40 PM - 01:55 PM PDT	Q&A	Questions and Answers Vijay K. Ramanan, MD, PhD
01:55 PM - 02:00 PM PDT	Break	Break
02:00 PM - 02:25 PM PDT	Speaker	Private practice experience
02:25 PM - 02:50 PM PDT	Speaker	Challengnig Cases in Evaluation of Eligibility Jonathan Graff-Radford, MD, FAAN
02:50 PM - 03:05 PM PDT	Speaker	Case Studies in the Management of ARIA Judith L. Heidebrink, MD
03:05 PM - 03:30 PM PDT	Speaker	When to When to Stop Anti-Amyloid Therapy and Biomarkers to Monitor for Target Engagement Vijay K. Ramanan, MD, PhD
03:30 PM - 04:00 PM PDT	Q&A	Questions and Answers

Faculty Disclosures
Jonathan Graff-Radford, MD, FAAN	Dr. Graff-Radford has received personal compensation for serving as an employee of Mayo Clinic. Dr. Graff-Radford has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NINDS/NIH. The institution of Dr. Graff-Radford has received research support from NIH. The institution of Dr. Graff-Radford has received research support from Eisai. The institution of Dr. Graff-Radford has received research support from Cognition therapeutics.
Vijay K. Ramanan, MD, PhD	The institution of Dr. Ramanan has received research support from the National Institutes of Health. The institution of Dr. Ramanan has received research support from the Mangurian Foundation for Lewy Body Disease Research. The institution of Dr. Ramanan has received research support from as part of clinical trials sponsored by the Alzheimer's Association, Eisai, the Alzheimer's Treatment and Research Institute at USC, and Transposon Therapeutics, Inc.. The institution of Dr. Ramanan has received research support from Medscape. Dr. Ramanan has received personal compensation in the range of $500-$4,999 for serving as a Conference Speaker/Organizer (Honoraria) with AANI.
Judith L. Heidebrink, MD	The institution of Dr. Heidebrink has received research support from Biohaven. The institution of Dr. Heidebrink has received research support from Eli Lilly. The institution of Dr. Heidebrink has received research support from Eisai. The institution of Dr. Heidebrink has received research support from NIH. The institution of Dr. Heidebrink has received research support from Alzheimer's Association. Dr. Heidebrink has received personal compensation in the range of $5,000-$9,999 for serving as a Faculty Member for the IMPACT-AD Clinical Trials course with the University of Southern California (funded by NIA/Alzheimer's Association).